McKesson Corp. (NYSE:MCK), San Francisco, CA, reported fiscal third-quarter revenues of $56.2 billion, up 5 percent compared to the year-ago period.
Sales in the company’s U.S. pharmaceutical and specialty solutions segment were $44.3 billion for the quarter, up 6 percent, driven primarily by market growth and acquisitions, the company said. European pharmaceutical solutions revenues were $6.9 billion for the quarter, down 1 percent compared to the year-ago period, driven primarily by market growth and partially offset by a reduction in the company’s owned retail pharmacies and a challenging operating environment in the U.K., the company said.
McKesson’s medical-surgical solutions segment revenues were $2 billion for the quarter, up 19 percent, driven primarily by an acquisition and market growth, according to the company.
